Precision Biosciences (DTIL) Share-based Compensation (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 45.11% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 108.29% decrease from a year earlier, with the FY2025 full-year figure at $259000.0, down 97.95% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.5 million, up from -$7.9 million in the prior quarter.
• Over the last five years, Share-based Compensation for DTIL reached as high as $16.7 million in Q3 2024 and fell as low as -$7.9 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.1 million in 2023.
• Across the five-year window, Share-based Compensation soared 437.84% in 2024 and plunged 320.83% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $4.5 million in 2022, then sank by 34.55% to $3.0 million in 2023, then advanced by 20.28% to $3.6 million in 2024, then tumbled by 320.83% to -$7.9 million in 2025, then soared by 119.64% to $1.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.5 million in Q1 2026, -$7.9 million in Q4 2025, and $2.4 million in Q3 2025.